Skip to main navigation Skip to search Skip to main content

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in Treatments of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation . . .

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date06/14/16 → 06/13/21

Funding

  • Astellas Pharma Global Development Incorporated: $24,753.34